Assignee
SUGIYAMA HARUO
JP·25 granted patents·3 pending applications·220 citations·filing 1997–2012
Top patents by PatentIndex Score
28 records- 0197US8778350B2Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the sameSUGIYAMA HARUO·Filed 2012·Granted Jul 15, 2014·16 cites·12 claims
- 0294US8105604B2WT1 modified peptideSUGIYAMA HARUO·Filed 2009·Granted Jan 31, 2012·20 cites·5 claims
- 0393US8557779B2Cancer vaccine compositionSUGIYAMA HARUO·Filed 2008·Granted Oct 15, 2013·14 cites·4 claims
- 0492US8388975B2Cancer antigen peptides derived from WT1SUGIYAMA HARUO·Filed 2009·Granted Mar 5, 2013·15 cites·6 claims
- 0591US9403886B2Tumor antigen based on products of the tumor suppressor gene WT1SUGIYAMA HARUO·Filed 2008·Granted Aug 2, 2016·11 cites·8 claims
- 0691US9266932B2Cancer antigen helper peptideSUGIYAMA HARUO·Filed 2010·Granted Feb 23, 2016·11 cites·12 claims
- 0791US8759483B2HLA-A* 3303-restricted WT1 peptide and pharmaceutical composition comprising the sameSUGIYAMA HARUO·Filed 2007·Granted Jun 24, 2014·5 cites·5 claims
- 0890US10093977B2Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of themSUGIYAMA HARUO·Filed 2008·Granted Oct 9, 2018·6 cites·3 claims
- 0987US9803246B2Receptor gene for peptide cancer antigen-specific T cellSUGIYAMA HARUO·Filed 2012·Granted Oct 31, 2017·5 cites·10 claims
- 1087US6225051B1Method of detecting solid cancer cells and tissue atypia and method of testing tissues for use in bone marrow transplantation and peripheral blood stem cell transplantationSUGIYAMA HARUO·Filed 1997·Granted May 1, 2001·80 cites·7 claims
- 1185US8288355B2siRNA specific to WT1 17AA(−)isoform and use thereofSUGIYAMA HARUO·Filed 2007·Granted Oct 16, 2012·9 cites·18 claims
- 1282US8653038B2HLA-A* 1101-restricted WT1 peptide and pharmaceutical composition comprising the sameSUGIYAMA HARUO·Filed 2007·Granted Feb 18, 2014·3 cites·11 claims
- 1381US8735357B2Method of inducing antigen-specific T cellsSUGIYAMA HARUO·Filed 2002·Granted May 27, 2014·9 cites·6 claims
- 1481US7824865B2Method for examining WT1-related diseaseSUGIYAMA HARUO·Filed 2005·Granted Nov 2, 2010·6 cites·4 claims
- 1580US10654892B2Method for activating helper T cellSUGIYAMA HARUO·Filed 2011·Granted May 19, 2020·3 cites·20 claims
- 1680US10139395B2Method for activation of helper T cell and composition for use in the methodSUGIYAMA HARUO·Filed 2008·Granted Nov 27, 2018·2 cites·19 claims
- 1775US8299234B2siRNA hat inhibits WT1 gene expression and uses thereofSUGIYAMA HARUO·Filed 2005·Granted Oct 30, 2012·2 cites·27 claims
- 1874US10265389B2Cancer antigen eEF2SUGIYAMA HARUO·Filed 2010·Granted Apr 23, 2019·2 cites·5 claims
- 1971US8242084B2Dimerized peptideSUGIYAMA HARUO·Filed 2010·Granted Aug 14, 2012·1 cites·4 claims
- 2055US9851356B2Method for measuring anti-WT1 antibodySUGIYAMA HARUO·Filed 2012·Granted Dec 26, 2017·0 cites·10 claims
- 2155US9086415B2Method for examining WT1-related diseaseSUGIYAMA HARUO·Filed 2010·Granted Jul 21, 2015·0 cites·5 claims
- 2255US7696180B2Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting substance against Wilms' tumor gene (WT1)SUGIYAMA HARUO·Filed 2005·Granted Apr 13, 2010·0 cites·6 claims
- 2353US8603997B2siRNA that inhibits WT1 gene expression and uses thereofSUGIYAMA HARUO·Filed 2012·Granted Dec 10, 2013·0 cites·40 claims
- 2449US2006217297A1Dimerized peptideSUGIYAMA HARUO·Filed 2004·Application pending·0 cites
- 2548US10500257B2Method of selecting WT1 vaccine adaptive patientSUGIYAMA HARUO·Filed 2004·Granted Dec 10, 2019·0 cites·16 claims
- 2647US7173111B2Wt1-interacting protein WTIPSUGIYAMA HARUO·Filed 2001·Granted Feb 6, 2007·0 cites·5 claims
- 2742US2008003637A1Methods for Separating Hepatic, Endothelial, or Hematopoietic Progenitor Cells From Cell PopulationsSUGIYAMA HARUO·Filed 2005·Application pending·0 cites
- 2840US2008038819A1Micro Rna Inhibiting the Expression of Wt1 Gene and Utilization of the SameSUGIYAMA HARUO·Filed 2005·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →